Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow

Samsung Bioepis announced the US relaunch of BYOOVIZ, the first interchangeable ophthalmology biosimilar to Lucentis, in partnership with Harrow. Harrow assumes full commercialization responsibilities for BYOOVIZ and OPUVIZ in the US, following the transition of rights from Biogen at the end of 2025.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.